Retrospective Review of Lucentis “Treat and Extend” Patterns and Outcomes in Age-Related Macular Degeneration

Chen, Yufeng N.; Powell, Anne-Marie; Mao, Alex; Sheidow, Tom

doi:10.1097/iae.0000000000000691

Cited by 10 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, based on clinical reports, a proactive T&E regimen has been shown to provide better functional outcomes than a PRN regimen with fewer treatment visits and with a mean of approximately 6 to 8 injections during the first year of treatment. 18,23,33,34 To summarize, ranibizumab 0.5 mg administered according to a T&E regimen was statistically noninferior and clinically comparable with a ranibizumab monthly regimen in improving VA from baseline to the end of study in patients with nAMD. Patients in both treatment groups achieved a rapid initial gain in BCVA, which was maintained up to the end of study.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

“…It offers opportunities to individualize patient management while minimizing treatment burden and costs associated with patient care. 33…”

Section: Discussionmentioning

confidence: 99%

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The TREX-AMD trial included 60 patients (2:1 randomization to T&E and monthly) and by the end of year 2, many data points were missing . All other T&E trials are either prospective or retrospective single-arm trials or noncontrolled studies looking at different T&E regimens to determine whether VA outcomes are not worse compared with monthly treatment. Hence, there is a need for large randomized clinical trials comparing the T&E approach with monthly treatment beyond 12 months.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at 12 months, to date there are few data on 24-month T&E trials compared with monthly dosing. OBJECTIVE To compare the efficacy of ranibizumab using a T&E regimen to monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD) after 24 months. DESIGN, SETTING, AND PARTICIPANTS A randomized, open-label, multicenter, noninferiority intention-to-treat trial with a margin of −5 letters in best-corrected visual acuity (BCVA) from baseline to 12 months between groups was conducted at 27 treatment centers in Canada. Participants included 580 patients with treatment-naive choroidal neovascularization secondary to AMD.

show abstract

“…The comparative efficacy between TAE and fixed monthly administration has also been described in numerous other studies, both retrospectively and prospectively. For example, Chen et al demonstrated in a retrospective analysis that eyes undergoing monthly vs. TAE treatment at 1 year on average had a visual difference of −0.5 letters (p = 0.81) [47]. Additionally, Abedi et al demonstrated in a prospective cohort study of 120 eyes, average visual gains of 9.5 letters and 8.0 letters at 12 and 24 months, respectively, which were comparable to those of the pivotal clinical trials [48].…”

Section: Treat-and-extend (Tae) and Treat-extend-stop (Tes) Methodsmentioning

confidence: 99%

Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration

Chaili¹,

Adrean²

2020

Visual Impairment and Blindness - What We Know and What We Have to Know

View full text Add to dashboard Cite

The purpose of this chapter is to examine the various treatment strategies used to manage neovascular age-related macular degeneration (nAMD). The chapter will focus on the three main strategies including fixed interval dosing, as needed Pro-Re-Nata (PRN) treatment and Treat-and-Extend (TAE), with its variant the Treat-Extend-Stop (TES) protocol. We will discuss the visual results of randomized clinical trials and retrospective studies using these methodologies and compare their outcomes, the pros and cons of each treatment strategy, as well as the underlying mechanisms that may explain these differences. The results of long-term extension trials following landmark randomized clinical studies and other long-term retrospective studies will also be compared to studies using a fixed interval dosing or the TAE/ TES method. We will also focus on the visual results of the TES protocol and examine recurrence rates, proposing a definition of the recurrence of choroidal neovascularization (CNV) versus increased disease activity. These topics discussed will help optimize anti-VEGF treatment regimens for patients with nAMD over the long term.

show abstract

Retrospective Review of Lucentis “Treat and Extend” Patterns and Outcomes in Age-Related Macular Degeneration

Abstract: Treat and Extend dosing regimen allows similar visual outcomes to monthly dosing, while reducing the total number of injections, visits, and overall cost.

Cited by 10 publications

References 14 publications

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease

Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About